AGIOS PHARMACEUTICALS

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

14 5 2025 09:00:00 提供 Nasdaq GlobeNewswire

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

09 5 2025 06:00:00 提供 Nasdaq GlobeNewswire

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

02 5 2025 06:00:00 提供 Nasdaq GlobeNewswire

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

01 5 2025 05:30:00 提供 Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

17 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

09 4 2025 08:57:01 提供 NetDania Notify

NetDania - New 12 months Low: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

08 4 2025 12:50:06 提供 NetDania Notify

NetDania - New 12 months Low: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

07 4 2025 08:45:27 提供 NetDania Notify

NetDania - New 12 months Low: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

04 4 2025 08:58:04 提供 NetDania Notify

NetDania - New 12 months Low: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

01 4 2025 12:49:16 提供 NetDania Notify

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

05 3 2025 16:52:45 提供 Nasdaq GlobeNewswire

Agios to Present at Upcoming Investor Conferences

04 3 2025 06:00:00 提供 Nasdaq GlobeNewswire

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

20 2 2025 06:00:00 提供 Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

13 2 2025 05:31:00 提供 Nasdaq GlobeNewswire

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

13 2 2025 05:30:00 提供 Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

06 2 2025 06:00:00 提供 Nasdaq GlobeNewswire

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

13 1 2025 06:00:00 提供 Nasdaq GlobeNewswire

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

08 1 2025 06:00:00 提供 Nasdaq GlobeNewswire

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

03 1 2025 06:00:00 提供 Nasdaq GlobeNewswire

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

18 12 2024 06:00:00 提供 Nasdaq GlobeNewswire